New compounds able to control hepatic cholesterol metabolism: Is it possible to avoid statin treatment in aged people?

World Journal of Hepatology

Volumn 5, Issue 12, 2013, Pages 676-684

  Trapani, Laura ^a   Segatto, Marco ^a   Pallottini, Valentina ^a  

^a ROMA TRE UNIVERSITY   (Italy)

Author keywords

Aging; Cholesterol; Hypercholesterolemia

Indexed keywords

EID: 84892875034     PISSN: None     EISSN: 19485182     Source Type: Journal    
DOI: 10.4254/wjh.v5.i12.676     Document Type: Article

References (74)

1. da Rocha JT, Trapani L, Segatto M, La Rosa P, Nogueira CW, Zeni G, Pallottini V. Molecular effects of diphenyl diselenide on cholesterol and glucose cell metabolism. Curr Med Chem 2013; 20: 4426-4434 [PMID: 23590714]
2. Kotsaftis P, Ntaios G, Savopoulos C, Kiparoglou R, Agapakis D, Baltatzi M, Tsesmeli N, Hatzitolios A. Trend in incidence of cardiovascular risk factors in elderly and overaged stroke patients between 2003 and 2007 in Greece. Arch Gerontol Geriatr 2010; 50: e31-e35 [PMID: 19520441 DOI: 10.1016/j.archger.2009.05.002]
3. Li W, Prakash R, Chawla D, Du W, Didion SP, Filosa JA, Zhang Q, Brann DW, Lima VV, Tostes RC, Ergul A. Early effects of high-fat diet on neurovascular function and focal ischemic brain injury. Am J Physiol Regul Integr Comp Physiol 2013; 304: R1001-R1008 [PMID: 23576615 DOI: 10.1152/ajpregu. 00523.2012]
4. Grundy SM, Cleeman JI, Merz CN, Brewer HB, Clark LT, Hunninghake DB, Pasternak RC, Smith SC, Stone NJ. Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III guidelines. Arterioscler Thromb Vasc Biol 2004; 24: e149-e161 [PMID: 15297292]
5. Finch CE, Tanzi RE. Genetics of aging. Science 1997; 278: 407-411 [PMID: 9334291 DOI: 10.1126/science.278.5337.407]
6. Holliday R. Somatic mutations and ageing. Mutat Res 2000; 463: 173-178 [PMID: 11018740 DOI: 10.1016/S1383-5742(00)00048-X]
7. Carnes BA, Olshansky SJ, Grahn D. Biological evidence for limits to the duration of life. Biogerontology 2003; 4: 31-45 [PMID: 12652187]
8. Korpelainen H. Fitness, reproduction and longevity among European aristocratic and rural Finnish families in the 1700s and 1800s. Proc Biol Sci 2000; 267: 1765-1770 [PMID: 12233775 DOI: 10.1098/rspb.2000.1208]
9. Gudmundsson H, Gudbjartsson DF, Frigge M, Gulcher JR, Stefánsson K. Inheritance of human longevity in Iceland. Eur J Hum Genet 2000; 8: 743-749 [PMID: 11039573 DOI: 10.1038/ sj.ejhg.5200527]
10. Wang DQ. Aging per se is an independent risk factor for cholesterol gallstone formation in gallstone susceptible mice. J Lipid Res 2002; 43: 1950-1959 [PMID: 12401894 DOI: 10.1194/jlr.M200078-JLR200]
11. Segatto M, Trapani L, Marino M, Pallottini V. Age-and sexrelated differences in extra-hepatic low-density lipoprotein receptor. J Cell Physiol 2011; 226: 2610-2616 [PMID: 21792919 DOI: 10.1002/jcp.22607]
12. Trapani L, Pallottini V. Age-Related Hypercholesterolemia and HMG-CoA Reductase Dysregulation: Sex Does Matter (A Gender Perspective). Curr Gerontol Geriatr Res 2010 May 4; Epub ahead of print [PMID: 20454643]
13. Trapani L, Segatto M, Incerpi S, Pallottini V. 3-Hydroxy-3-methylglutaryl coenzyme A reductase regulation by antioxidant compounds: new therapeutic tools for hypercholesterolemia. Curr Mol Med 2011; 11: 790-797 [PMID: 21999146 DOI: 10.2174/156652411798062403]
14. Marino M, Pallottini V, D'Eramo C, Cavallini G, Bergamini E, Trentalance A. Age-related changes of cholesterol and dolichol biosynthesis in rat liver. Mech Ageing Dev 2002; 123: 1183-1189 [PMID: 12044967 DOI: 10.1016/S0047-6374(02)00009-X]
15. Pallottini V, Martini C, Pascolini A, Cavallini G, Gori Z, Bergamini E, Incerpi S, Trentalance A. 3-Hydroxy-3-methylglutaryl coenzyme A reductase deregulation and age-related hypercholesterolemia: a new role for ROS. Mech Ageing Dev 2005; 126: 845-851 [PMID: 15992608 DOI: 10.1016/ j.mad.2005.02.009]
16. Pallottini V, Martini C, Cavallini G, Bergamini E, Mustard KJ, Hardie DG, Trentalance A. Age-related HMG-CoA reductase deregulation depends on ROS-induced p38 activation. Mech Ageing Dev 2007; 128: 688-695 [PMID: 18031790 DOI: 10.1016/j.mad.2007.10.001]
17. Trapani L, Pallottini V. Hypercholesterolemia and 3-hydroxy 3-methylglutaryl Coenzyme A reductase regulation during ageing. ScientificWorldJournal 2009; 9: 564-574 [PMID: 19578714 DOI: 10.1100/tsw.2009.81]
18. Trapani L, Violo F, Pallottini V. Hypercholesterolemia and 3-hydroxy-3-methylglutaryl coenzyme A reductase regulation in aged female rats. Exp Gerontol 2010; 45: 119-128 [PMID: 19895880 DOI: 10.1016/j.exger.2009.10.014]
19. Trapani L, Segatto M, Ascenzi P, Pallottini V. Potential role of nonstatin cholesterol lowering agents. IUBMB Life 2011; 63: 964-971 [PMID: 21990243 DOI: 10.1002/iub.522]
20. Gotto AM. Statin therapy and the elderly: SAGE advice. Circulation 2007; 115: 681-683 [PMID: 17296867 DOI: 10.1161/ CIRCULATIONAHA.106.678300]
21. Istvan ES, Deisenhofer J. Structural mechanism for statin inhibition of HMG-CoA reductase. Science 2001; 292: 1160-1164 [PMID: 11349148 DOI: 10.1126/science.1059344]
22. Rozman D, Monostory K. Perspectives of the non-statin hypolipidemic agents. Pharmacol Ther 2010; 127: 19-40 [PMID: 20420853 DOI: 10.1016/j.pharmthera.2010.03.007]
23. Savopoulos CG, Hatzitolios AI, Katsiki NA, Baltatzi M, Kosmidou M, Raikos N, Mikhailidis DP, Ziakas AG, Kaiafa G, Tsesmeli N. Sodium-lithium countertransport activity in healthy, dyslipidemic, and hypertensive individuals. Angiology 2008; 59: 727-735 [PMID: 18840623 DOI: 10.1177/0003319 708319784]
24. Kosmidou MS, Hatzitolios AI, Adamidou A, Giannopoulos S, Raikos N, Parharidis G, Milionis HJ. Effects of atorvastatin on red-blood cell Na(+)/Li(+) countertransport in hyperlipidemic patients with and without hypertension. Am J Hypertens 2008; 21: 303-309 [PMID: 18202666 DOI: 10.1038/ ajh.2007.61]
25. Kosmidou M, Hatzitolios AI, Molyva D, Raikos N, Savopou-los C, Daferera N, Kokkas V, Goulas A. An association study between catalase -262C& gt; T gene polymorphism, sodiumlithium countertransport activity, insulin resistance, blood lipid parameters and their response to atorvastatin, in Greek dyslipidaemic patients and normolipidaemic controls. Free Radic Res 2009; 43: 385-389 [PMID: 19274593 DOI: 10.1080/10 715760902783293]
26. Callegari S, Gregory PA, Sykes MJ, Bellon J, Andrews S, McKinnon RA, de Barros Lopes MA. Polymorphisms in the mitochondrial ribosome recycling factor EF-G2mt/MEF2 compromise cell respiratory function and increase atorvastatin toxicity. PLoS Genet 2012; 8: e1002755 [PMID: 22719265 DOI: 10.1371/journal.pgen.1002755]
27. Elens L, Becker ML, Haufroid V, Hofman A, Visser LE, Uitterlinden AG, Stricker BCh, van Schaik RH. Novel CYP3A4 intron 6 single nucleotide polymorphism is associated with simvastatin-mediated cholesterol reduction in the Rotterdam Study. Pharmacogenet Genomics 2011; 21: 861-866 [PMID: 21946898 DOI: 10.1097/FPC.0b013e32834c6edb]
28. Hutz MH, Fiegenbaum M. Impact of genetic polymorphisms on the efficacy of HMG-CoA reductase inhibitors. Am J Cardiovasc Drugs 2008; 8: 161-170 [PMID: 18533737 DOI: 10.2165 /00129784-200808030-00003]
29. Cham S, Evans MA, Denenberg JO, Golomb BA. Statinassociated muscle-related adverse effects: a case series of 354 patients. Pharmacotherapy 2010; 30: 541-553 [PMID: 20500044 DOI: 10.1592/phco.30.6.541]
30. Trapani L, Melli L, Segatto M, Trezza V, Campolongo P, Jozwiak A, Swiezewska E, Pucillo LP, Moreno S, Fanelli F, Linari M, Pallottini V. Effects of myosin heavy chain (MHC) plasticity induced by HMGCoA-reductase inhibition on skeletal muscle functions. FASEB J 2011; 25: 4037-4047 [PMID: 21798954 DOI: 10.1096/fj.11-184218]
31. Martini C, Pallottini V, De Marinis E, Marino M, Cavallini G, Donati A, Straniero S, Trentalance A. Omega-3 as well as caloric restriction prevent the age-related modifications of cholesterol metabolism. Mech Ageing Dev 2008; 129: 722-727 [PMID: 18930075 DOI: 10.1016/j.mad.2008.09.010]
32. Sevov M, Elfineh L, Cavelier LB. Resveratrol regulates the expression of LXR-alpha in human macrophages. Biochem Biophys Res Commun 2006; 348: 1047-1054 [PMID: 16901463 DOI: 10.1016/j.bbrc.2006.07.155]
33. Cho IJ, Ahn JY, Kim S, Choi MS, Ha TY. Resveratrol attenuates the expression of HMG-CoA reductase mRNA in hamsters. Biochem Biophys Res Commun 2008; 367: 190-194 [PMID: 18166149 DOI: 10.1016/j.bbrc.2007.12.140]
34. Sesso HD, Gaziano JM, Liu S, Buring JE. Flavonoid intake and the risk of cardiovascular disease in women. Am J Clin Nutr 2003; 77: 1400-1408 [PMID: 12791616]
35. Punithavathi VR, Prince PS. Combined effects of quercetin and alpha-tocopherol on lipids and glycoprotein components in isoproterenol induced myocardial infarcted Wistar rats. Chem Biol Interact 2009; 181: 322-327 [PMID: 19595682 DOI: 10.1016/j.cbi.2009.07.002]
36. Brown GR, Hollinshead DM, Stokes ES, Clarke DS, Eakin MA, Foubister AJ, Glossop SC, Griffiths D, Johnson MC, Mc-Taggart F, Mirrlees DJ, Smith GJ, Wood R. Quinuclidine inhibitors of 2,3-oxidosqualene cyclase-lanosterol synthase: optimization from lipid profiles. J Med Chem 1999; 42: 1306-1311 [PMID: 10197973 DOI: 10.1021/jm990038q]
37. Lee SH, Park YB, Bae KH, Bok SH, Kwon YK, Lee ES, Choi MS. Cholesterol-lowering activity of naringenin via inhibition of 3-hydroxy-3-methylglutaryl coenzyme A reductase and acyl coenzyme A: cholesterol acyltransferase in rats. Ann Nutr Metab 1999; 43: 173-180 [PMID: 10545673 DOI: 10.1159/000012783]
38. Song BL, DeBose-Boyd RA. Insig-dependent ubiquitination and degradation of 3-hydroxy-3-methylglutaryl coenzyme a reductase stimulated by delta-and gamma-tocotrienols. J Biol Chem 2006; 281: 25054-25061 [PMID: 16831864 DOI: 10.1074/jbc.M605575200]
39. Qureshi AA, Burger WC, Peterson DM, Elson CE. The structure of an inhibitor of cholesterol biosynthesis isolated from barley. J Biol Chem 1986; 261: 10544-10550 [PMID: 3733719]
40. Borges F, Roleira F, Milhazes N, Santana L, Uriarte E. Simple coumarins and analogues in medicinal chemistry: occurrence, synthesis and biological activity. Curr Med Chem 2005; 12: 887-916 [PMID: 15853704 DOI: 10.2174/0929867053507315]
41. Pedersen JZ, Oliveira C, Incerpi S, Kumar V, Fiore AM, De Vito P, Prasad AK, Malhotra SV, Parmar VS, Saso L. Antioxidant activity of 4-methylcoumarins. J Pharm Pharmacol 2007; 59: 1721-1728 [PMID: 18053335 DOI: 10.1211/jpp.59.12.0015]
42. Trapani L, Segatto M, Simeoni V, Balducci V, Dhawan A, Parmar VS, Prasad AK, Saso L, Incerpi S, Pallottini V. Short-and long-term regulation of 3-hydroxy 3-methylglutaryl coenzyme A reductase by a 4-methylcoumarin. Biochimie 2011; 93: 1165-1171 [PMID: 21530605 DOI: 10.1016/ j.biochi.2011.04.009]
43. da Rocha JT, Pinton S, Mazzanti A, Mazzanti CM, Beckemann DV, Nogueira CW, Zeni G. Diphenyl diselenide ameliorates cognitive deficits induced by a model of menopause in rats. Behav Pharmacol 2012; 23: 98-104 [PMID: 22139607 DOI: 10.1097/FBP.0b013e32834ed849]
44. da Rocha JT, Sampaio TB, Santos Neto JS, Nogueira CW, Zeni G. Cognitive effects of diphenyl diselenide and estradiol treatments in ovariectomized mice. Neurobiol Learn Mem 2013; 99: 17-24 [PMID: 23085182 DOI: 10.1016/j.nlm.2012.10.005]
45. de Bem AF, Farina M, Portella Rde L, Nogueira CW, Dinis TC, Laranjinha JA, Almeida LM, Rocha JB. Diphenyl diselenide, a simple glutathione peroxidase mimetic, inhibits human LDL oxidation in vitro. Atherosclerosis 2008; 201: 92-100 [PMID: 18440006 DOI: 10.1016/j.atherosclerosis.2008.02.030]
46. da Rocha JT, Sperança A, Nogueira CW, Zeni G. Hypolipidaemic activity of orally administered diphenyl diselenide in Triton WR-1339-induced hyperlipidaemia in mice. J Pharm Pharmacol 2009; 61: 1673-1679 [PMID: 19958591]
47. Hort MA, Straliotto MR, Netto PM, da Rocha JB, de Bem AF, Ribeiro-do-Valle RM. Diphenyl diselenide effectively reduces atherosclerotic lesions in LDLr -/-mice by attenuation of oxidative stress and inflammation. J Cardiovasc Pharmacol 2011; 58: 91-101 [PMID: 21558882]
48. Altmann SW, Davis HR, Zhu LJ, Yao X, Hoos LM, Tetzloff G, Iyer SP, Maguire M, Golovko A, Zeng M, Wang L, Murgolo N, Graziano MP. Niemann-Pick C1 Like 1 protein is critical for intestinal cholesterol absorption. Science 2004; 303: 1201-1204 [PMID: 14976318 DOI: 10.1126/science.1093131]
49. Ge L, Wang J, Qi W, Miao HH, Cao J, Qu YX, Li BL, Song BL. The cholesterol absorption inhibitor ezetimibe acts by blocking the sterol-induced internalization of NPC1L1. Cell Metab 2008; 7: 508-519 [PMID: 18522832 DOI: 10.1016/ j.cmet.2008.04.001]
50. Pandor A, Ara RM, Tumur I, Wilkinson AJ, Paisley S, Duenas A, Durrington PN, Chilcott J. Ezetimibe monotherapy for cholesterol lowering in 2,722 people: systematic review and meta-analysis of randomized controlled trials. J Intern Med 2009; 265: 568-580 [PMID: 19141093]
51. Sallam A, Kashani S, Sherafat H. Healon5 and corneal wound burn during phacoemulsification. J Cataract Refract Surg 2007; 33: 754; author reply 754-755 [PMID: 17466828]
52. Thomas JE, Tershakovec AM, Jones-Burton C, Sayeed RA, Foody JM. Lipid lowering for secondary prevention of cardiovascular disease in older adults. Drugs Aging 2010; 27: 959-972 [PMID: 21087066 DOI: 10.2165/11539550-000000000-00000]
53. Hatzitolios A, Savopoulos C, Lazaraki G, Sidiropoulos I, Haritanti P, Lefkopoulos A, Karagiannopoulou G, Tzioufa V, Dimitrios K. Efficacy of omega-3 fatty acids, atorvastatin and orlistat in non-alcoholic fatty liver disease with dyslipidemia. Indian J Gastroenterol 2004; 23: 131-134 [PMID: 15333967]
54. Han TS, Tajar A, Lean ME. Obesity and weight management in the elderly. Br Med Bull 2011; 97: 169-196 [PMID: 21325341 DOI: 10.1093/bmb/ldr002]
55. Sakai T, Kamanna VS, Kashyap ML. Niacin, but not gemfibrozil, selectively increases LP-AI, a cardioprotective subfraction of HDL, in patients with low HDL cholesterol. Arterioscler Thromb Vasc Biol 2001; 21: 1783-1789 [PMID: 11701466 DOI: 10.1161/hq1001.096624]
56. Vosper H. Niacin: a re-emerging pharmaceutical for the treatment of dyslipidaemia. Br J Pharmacol 2009; 158: 429-441 [PMID: 19627285 DOI: 10.1111/j.1476-5381.2009.00349.x]
57. Kühnast S, Louwe MC, Heemskerk MM, Pieterman EJ, van Klinken JB, van den Berg SA, Smit JW, Havekes LM, Rensen PC, van der Hoorn JW, Princen HM, Jukema JW. Niacin Reduces Atherosclerosis Development in APOE 3Leiden. CETP Mice Mainly by Reducing NonHDL-Cholesterol. PLoS One 2013; 8: e66467 [PMID: 23840481 DOI: 10.1371/journal. pone.0066467]
58. Tenenbaum A, Fisman EZ. Fibrates are an essential part of modern anti-dyslipidemic arsenal: spotlight on atherogenic dyslipidemia and residual risk reduction. Cardiovasc Diabetol 2012; 11: 125 [PMID: 23057687]
59. Davidson MH. Novel nonstatin strategies to lower lowdensity lipoprotein cholesterol. Curr Atheroscler Rep 2009; 11: 67-70 [PMID: 19080731 DOI: 10.1007/s11883-009-0011-0]
60. Meade T, Zuhrie R, Cook C, Cooper J. Bezafibrate in men with lower extremity arterial disease: randomised controlled trial. BMJ 2002; 325: 1139 [PMID: 12433762 DOI: 10.1136/ bmj.325.7373.1139]
61. Merki E, Graham MJ, Mullick AE, Miller ER, Crooke RM, Pitas RE, Witztum JL, Tsimikas S. Antisense oligonucleotide directed to human apolipoprotein B-100 reduces lipoprotein(a) levels and oxidized phospholipids on human apolipoprotein B-100 particles in lipoprotein(a) transgenic mice. Circulation 2008; 118: 743-753 [PMID: 18663084 DOI: 10.1161/CIRCULATIONAHA.108.786822]
62. Bays HE, Neff D, Tomassini JE, Tershakovec AM. Ezetimibe: cholesterol lowering and beyond. Expert Rev Cardiovasc Ther 2008; 6: 447-470 [PMID: 18402536 DOI: 10.1586/14779072.6.4. 447]
63. Huang LZ, Zhu HB. Novel LDL-oriented pharmacotherapeutical strategies. Pharmacol Res 2012; 65: 402-410 [PMID: 22306845 DOI: 10.1016/j.phrs.2012.01.007]
64. Peterson AS, Fong LG, Young SG. PCSK9 function and physiology. J Lipid Res 2008; 49: 1595-1599 [PMID: 18663786]
65. Seidah NG, Prat A. The biology and therapeutic targeting of the proprotein convertases. Nat Rev Drug Discov 2012; 11: 367-383 [PMID: 22679642 DOI: 10.1038/nrd3699]
66. Graham MJ, Lemonidis KM, Whipple CP, Subramaniam A, Monia BP, Crooke ST, Crooke RM. Antisense inhibition of proprotein convertase subtilisin/kexin type 9 reduces serum LDL in hyperlipidemic mice. J Lipid Res 2007; 48: 763-767 [PMID: 17242417 DOI: 10.1194/jlr.C600025-JLR200]
67. Gupta N, Fisker N, Asselin MC, Lindholm M, Rosenbohm C, Ørum H, Elmén J, Seidah NG, Straarup EM. A locked nucleic acid antisense oligonucleotide (LNA) silences PCSK9 and enhances LDLR expression in vitro and in vivo. PLoS One 2010; 5: e10682 [PMID: 20498851 DOI: 10.1371/journal. pone.0010682]
68. Shan L, Pang L, Zhang R, Murgolo NJ, Lan H, Hedrick JA. PCSK9 binds to multiple receptors and can be functionally inhibited by an EGF-A peptide. Biochem Biophys Res Commun 2008; 375: 69-73 [PMID: 18675252 DOI: 10.1016/ j.bbrc.2008.07.106]
69. Duff CJ, Scott MJ, Kirby IT, Hutchinson SE, Martin SL, Hooper NM. Antibody-mediated disruption of the interaction between PCSK9 and the low-density lipoprotein receptor. Biochem J 2009; 419: 577-584 [PMID: 19196236 DOI: 10.1042/BJ20082407]
70. Lambert G, Sjouke B, Choque B, Kastelein JJ, Hovingh GK. The PCSK9 decade. J Lipid Res 2012; 53: 2515-2524 [PMID: 22811413 DOI: 10.1194/jlr.R026658]
71. Petrides F, Shearston K, Chatelais M, Guilbaud F, Meilhac O, Lambert G. The promises of PCSK9 inhibition. Curr Opin Lipidol 2013; 24: 307-312 [PMID: 23817198 DOI: 10.1097/ MOL.0b013e328361f62d]
72. Chen XW, Wang H, Bajaj K, Zhang P, Meng ZX, Ma D, Bai Y, Liu HH, Adams E, Baines A, Yu G, Sartor MA, Zhang B, Yi Z, Lin J, Young SG, Schekman R, Ginsburg D. SEC24A deficiency lowers plasma cholesterol through reduced PCSK9 secretion. Elife 2013; 2: e00444 [PMID: 23580231]
73. Lee SN, Prodhomme E, Lindberg I. Prohormone convertase 1 (PC1) processing and sorting: effect of PC1 propeptide and proSAAS. J Endocrinol 2004; 182: 353-364 [PMID: 15283695 DOI: 10.1677/joe.0.1820353]
74. Marazzi G, Cacciotti L, Pelliccia F, Iaia L, Volterrani M, Caminiti G, Sposato B, Massaro R, Grieco F, Rosano G. Long-term effects of nutraceuticals (berberine, red yeast rice, policosanol) in elderly hypercholesterolemic patients. Adv Ther 2011; 28: 1105-1113 [PMID: 22113535 DOI: 10.1007/ s12325-011-0082-5]